The Drug-Induced Respiratory Disease Website and App
Frequency - Incidence
Incidence of respiratory adverse event(s) due to the specific drug as assessed by number of reported/published cases in the literature. Red digits in stars indicate: 0 = Very rare, questionable signal · 1 = < 10 cases · 2 = 10-50 cases · 3 = 50–100 cases · 4 = 100-200 cases · 5 = >200 cases
Evidence level/grade
Evidence level for respiratory adverse event(s) due to the specific drug as estimated using Hill’s (1965), Naranjo’s (1981), and Bégaud’s (1985) criteria applied to published cases. Blue digits in stars indicate: 0 = Questionable · 1 = Low · 2 = Moderate · 3 = Robust · 4 = Definite · 5 = Unquestionable, pathognomonic
Lymphadenopathy (intrathoracic)
Publications
Sagawa T, Sato Y, Nagashima H, Takada K, Takahashi M, Hirakawa M, Hamaguchi K, Tamura F, Fujikawa K, Okamoto K, Kawano Y, Sogabe M, Miyamoto H, Takayama T
Hilar/mediastinal and cutaneous drug-induced sarcoidosis-like reaction associated with immune checkpoint inhibitors in metastatic colorectal cancer: a case report.
Frontiers in immunology 2023;14;1203621 — 2023 — 1203621
Cascone T, Weissferdt A, Godoy MCB, William WN, Leung CH, Lin HY, Basu S, Yadav SS, Pataer A, Mitchell KG, Khan MAW, Shi Y, Haymaker C, Solis LM, Parra ER, Kadara H, Wistuba II, Sharma P, Allison JP, Ajami NJ, Wargo JA, Jenq RR, Gibbons DL, Lee JJ, Swishe
Nodal immune flare mimics nodal disease progression following neoadjuvant immune checkpoint inhibitors in non-small cell lung cancer.
Nature communications 2021 08 19;12;5045 — 2021 08 19 — 5045
Sarcoidosis-Like Reactions Induced by Checkpoint Inhibitors.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2018 08;13;1076-1082 — 2018 08 — 1076-1082
Pulmonary Infiltrates in a Patient With Advanced Melanoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2017 Mar;35;705-708 — 2017 Mar — 705-708
Radiologic manifestations of immune-related adverse events in patients with metastatic melanoma undergoing anti-CTLA-4 antibody therapy.
AJR. American journal of roentgenology 2011 Dec;197;W992-W1000 — 2011 Dec — W992-W1000